Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03408665 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

Study acronym: STEREOLIVER
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 11 to 12v9
  2. Study completion date: Dec 1, 2027 to Jan 2027v8
  3. Re-verified, no change to tracked fieldsv7
  4. Primary completion date: Mar 13, 2026 to Dec 1, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 11 to 7
    • Study completion date: Mar 13, 2027 to Dec 1, 2027
    v6
  5. Re-verified, no change to tracked fieldsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary endpoint revised
    • Study sites: 10 to 11
    • Secondary endpoints revised (11)
    • Eligibility criteria shortened, about 3 words
    v4
  2. Study sites: 8 to 10
    • Collaborators expanded, about 3 words
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jan 2025 to Mar 13, 2026
    • Start date changed from estimate of Jan 2018 to Mar 13, 2019
    • Study completion date: Jan 2026 to Mar 13, 2027
    • Site details revised at 8 of 8 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Centre Oscar Lambret
100 trials monitored
See 2 trials at risk
Liver Cancer
1,598 trials monitored
See 71 trials at risk
Intervention research involving the human person, phase II, prospective, multicentric, non-randomized and multi-cohort study. The eligibility criteria are broad, on purpose, so every patient, able to be treated by SBRT and unable to participate in another trial (non eligible patient or non included centers), can be included in this national study, in a prospective way.
Trial Details
NCT Number NCT03408665
Lead Sponsor Centre Oscar Lambret
Collaborators: Canceropôle Nord Ouest
Conditions
(from sponsor)		 Liver Cancer, Liver Metastases
Related terms Liver Neoplasms
Enrollment 280 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov